scholarly journals Optimum treatment strategies for a recent left ventricular thrombus

2019 ◽  
Vol 18 (3) ◽  
pp. 158-161
Author(s):  
Tomáš Gistinger ◽  
Kamil Zeman ◽  
Ivo Pavlas
Keyword(s):  
Treatment Strategies ◽  
Left Ventricular ◽  
Left Ventricular Thrombus ◽  
Optimum Treatment ◽  
Ventricular Thrombus

scholarly journals The Prognostic Impact of Left Ventricular Thrombus Resolution after Acute Coronary Syndrome and Risk Modulation via Anti-Thrombotic Treatment Strategies

2021 ◽  
Author(s):  
Felix Hofer ◽  
Niema Kazem ◽  
Ronny Schweitzer ◽  
Patricia Horvat ◽  
Max-Paul Winter ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Patient Population ◽  
Treatment Strategies ◽  
Left Ventricular ◽  
Left Ventricular Thrombus ◽  
Prognostic Impact ◽  
Inverse Association ◽  
Long Term Outcome ◽  
Coronary Syndrome ◽  
Ventricular Thrombus

Abstract Background: Left ventricular thrombus (LVT) is a rare but dreaded complication during the acute phase of acute coronary syndrome (ACS). However, profound data on long-term outcome and associated anti-thrombotic treatment strategies of this highly vulnerable patient population are scarce in current literature. Methods: Patients presenting with ACS were screened for presence of LVT and subsequently included within a prospective clinical registry. All-cause mortality and the composite of MACE and thrombo-embolic events were defined as primary and secondary endpoint. Results: Within 43 patients presenting with LVT, thrombus resolution during patient follow-up was observed in 27 individuals (62.8%). Patients that reached a resolution of LVT experienced lower incidence rates of death (-23.9%; p=0.022), MACE (-37.8%; p=0.005) and thrombo-embolic events (-35.2%; p=0.008). Even after adjustment for clinical variables, thrombus resolution showed an independent inverse association with all-cause death with an hazard ratio (HR) of 0.14 (95%CI: 0.03-0.75; p=0.021) and as well as with MACE with a HR of 0.22 (95%CI: 0.07-0.68; p=0.008) and thrombo-embolic events with a HR of 0.22 (95%CI: 0.06-0.75; p=0.015). Triple antithrombotic therapy (TAT) with ticagrelor/prasugrel showed a strong and independent association with thrombus resolution with an adjusted HR of 3.25 (95%CI: 1.22-8.68; p=0.019) compared to other strategies. Conclusion: The presented data indicate a poor outcome of ACS patients experiencing LVT. In terms of a personalized risk stratification, thrombus resolution has a strong protective impact on both all-cause death and MACE with the potential to tailor treatment decisions – including an intensified anti-thrombotic treatment approach – in this patient population.

CONTEMPORARY ETIOLOGIES, TREATMENT STRATEGIES, AND OUTCOMES OF LEFT VENTRICULAR THROMBUS

2019 ◽  
Vol 73 (9) ◽  
pp. 716
Author(s):  
Cian McCarthy ◽  
Sean Murphy ◽  
Ramkumar V. Venkateswaran ◽  
Avinainder Singh ◽  
Leslie L. Chang ◽  
...  
Keyword(s):  
Treatment Strategies ◽  
Left Ventricular ◽  
Left Ventricular Thrombus ◽  
Ventricular Thrombus

scholarly journals LEFT VENTRICULAR THROMBUS CAUSED BY COVID-19: HOW LONG TO TREAT?

2021 ◽  
Vol 77 (18) ◽  
pp. 2013
Author(s):  
Hee D. Jeon ◽  
Jay Patel ◽  
Tiffany Priester ◽  
Marriyam Moten
Keyword(s):  
Left Ventricular ◽  
Left Ventricular Thrombus ◽  
Ventricular Thrombus

scholarly journals Large left ventricular thrombus surgically resected in a patient with normal ejection: A case report

2021 ◽  
Vol 81 ◽  
pp. 105842 ◽  
Author(s):  
Abdulkarim Abukhodair ◽  
Mohammed S. Alqarni ◽  
Abdulmalek Alzahrani ◽  
Ziad M. Bukhari ◽  
Khalid Zuber ◽  
...  
Keyword(s):  
Case Report ◽  
Left Ventricular ◽  
Left Ventricular Thrombus ◽  
Ventricular Thrombus
Sign in / Sign up

Export Citation Format

Share Document